- Region I: CT, MA, ME, NH, NJ, NY, PA, RI, VT
- Region II: DC, DE, MD, NC, VA
- Region III: GA, northern FL, SC
- Region IV: southern FL
- Region V: IN, KY, OH, TN, WV
- Region VI: AL, AR, LA, MS
- Region VII: MI, MN, WI
- Region VIII: IA, IL, MO
- Region IX: KS, NE, ND, SD
- Region X: OK, TX
- Region XI: AZ (mountains), CO, ID (mountains), MT, NM, UT, WY
- Region XII: AZ (south), CA (southeast desert)
- Region XIII: CA (southern coastal)
- Region XIV: CA (central valley)
- Region XV: ID (southern), NV
- Region XVI: OR (east), WA (central & east)
- Region XVII: CA (northwest), OR (west), WA (west)
- Region XVIII: AK
NEW LIVE WEBINAR
Clinical blind spots: Alpha-Gal, Asthma, and COPD in 2026
Understanding Alpha-gal syndrome and navigating the new asthma and current COPD HEDIS metrics
Gain practical, evidence-based insights to help you recognize and evaluate patients with suspected alpha-gal syndrome while learning how to successfully navigate the evolving asthma and COPD quality measures. We'll also discuss the growing role of allergic phenotyping and trigger identification in improving patient outcomes and supporting quality care.
Learning objectives:
- Recognize the clinical presentation and diagnostic approach to alpha-gal syndrome
- Understand how allergic phenotyping and identification of allergic triggers can improve diagnosis, treatment selection, and patient outcomes in asthma and COPD
- Apply practical strategies to support quality measure performance while delivering personalized respiratory care
- Build confidence in results interpretation for comprehensive allergy testing
You have 3 opportunities to join us for this innovative talk. Please select and register for the following times: